Clinical Trials Logo

Clinical Trial Summary

The purpose of this trial is to explore the preliminary efficacy of Chiauranib monotherapy in patients with advanced or unresectable soft tissue sarcoma who failed standard therapy, and the safety of Chiauranib monotherapy in patients with advanced or unresectable soft tissue sarcoma who failed standard therapy and the relationship between potential biomarkers and preliminary efficacy.


Clinical Trial Description

Chiauranib has not yet been approved for marketing at home and abroad. It is a small-molecule anti-tumor targeted drug targeting multiple protein kinases. It has a three-way anti-tumor synergistic mechanism, including anti-tumor angiogenesis, inhibiting tumor cell mitosis, and regulating tumor inflammatory microenvironment, and exerts a comprehensive anti-tumor effect; at the same time, its high target selectivity also reduces the risk of Risk of side effects from off-target effects. Chiauranib has shown preliminary anti-tumor effects in multiple tumor types clinically, among which, two tumor types, small cell lung cancer and ovarian cancer, have entered phase III clinical studies. Drugs with similar mechanisms of action, pazopanib, regorafenib, anlotinib, apatinib (VEGFR, etc.) and Alisertib (targeting Aurora A, etc.) single-agents have demonstrated certain anti-tumor activity in STS patients , which provides a certain reference for Chiauranib. The trial used a single-arm, open-label, multicenter design to explore the preliminary efficacy and safety of Chiauranib in patients with advanced or unresectable soft tissue sarcoma who had failed standard therapy. If a subtype or several subtypes are found to have better efficacy, or if the biomarker study suggests a relationship with the initial efficacy, further research in specific subtypes will be considered after discussion between the investigator and the sponsor. The whole experimental study includes three phases: screening period, treatment period and follow-up period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05542433
Study type Interventional
Source Sun Yat-sen University
Contact Xing Zhang, PhD, MD
Phone 86-020-87343192
Email zhangxing@sysucc.org.cn
Status Recruiting
Phase Phase 2
Start date August 2, 2022
Completion date August 2, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT02910895 - A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS) N/A
Recruiting NCT05621668 - A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted Il12 (Attil12)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma Phase 1
Active, not recruiting NCT04032964 - Dose Finding Study of L19TNF and Doxorubicin in Patients With STS Phase 1
Active, not recruiting NCT04577014 - Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma Phase 1/Phase 2
Completed NCT01650077 - Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria
Withdrawn NCT04906876 - A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas Phase 2
Terminated NCT02890368 - Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides Phase 1
Terminated NCT02628535 - Safety Study of MGD009 in B7-H3-expressing Tumors Phase 1
Completed NCT02204111 - Patient Directed Intervention to Improve the Quality of Life for Patients With Soft Tissue Sarcoma
Withdrawn NCT01663090 - Ferumoxytol-Enhanced MRI in Adult/Pedi Sarcomas N/A
Completed NCT01259375 - Amrubicin Chemotherapy as First Line in Metastatic or Unresectable Soft Tissue Sarcoma Phase 2
Completed NCT01440088 - A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Phase 3
Completed NCT01106872 - Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas Phase 1
Recruiting NCT00753727 - Sunitinib and Radiation in Patients With Resectable Soft-tissue Sarcoma Phase 1/Phase 2
Terminated NCT00755261 - Phase II Study of Doxorubicin and Avastin® in Sarcoma. Phase 2
Completed NCT00611078 - Environmental Pollutants and the Risk of Soft Tissue Sarcoma: A Pilot Study N/A
Completed NCT00580320 - Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma Phase 1
Completed NCT03452644 - US-Guided Biopsy in the Diagnosis of Musculoskeletal Soft-Tissue Tumors
Recruiting NCT05539677 - Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Terminated NCT03520959 - A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702) Phase 3